Clinical trial · Interventional
Advanced Diffusion Imaging in Renal Cancer Patients
Advanced Diffusion Imaging in Renal Cancer Patients: Oncologic Control and Renal Functional Reserve
NCT06116253CI-TRIAL-00110962active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cancer | Kidney Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Imaging (MRI) Scan | Device | — | UNRESOLVED |
| Tc-99m Pentetate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Renal Mass Patients
- description
- Patients will be enrolled for 2 MRI visits. These visits will include an approximately 1 hour research MRI scan and a total of between 3 and 5 hours Tc-99m DTPA scan. In each MRI visit, patients will be scanned for approximately one hour including both standard-of-care clinical sequences and research-based Advanced Diffusion Imaging sequences, on a Prisma 3T MRI scanner. Following the MRI exam or on a day not more than a week after the MRI exam, patients will undergo renal function assessment via Tc-99m DTPA scan and patient's kidneys will be scanned using a gamma camera. Proteinuria will be assessed by standard of care urinalysis of specimens collected at each MRI visit for each patient. Blood test will be performed at each visit to estimate GFR (eGFR) from measurement of serum creatinine.
- interventionNames
- Device: Magnetic Resonance Imaging (MRI) Scan
- Drug: Tc-99m Pentetate
Primary outcomes (1)
- measure
- Percentage of Times Lesion Type is Correctly Predicted using IVIM-MRI at Pre-Surgery
- timeFrame
- Baseline (1 Week Prior to Operation)
- description
- Intravoxel incoherent imaging-MRI (IVIM-MRI) data will be used to predict lesion type.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Renal mass patients scheduled for laparoscopic partial nephrectomy. * eGFR above 30 ml/min/m2. * Ages 21 to 85 * Must be willing and able to provide consent. Exclusion Criteria: * All metal implants and dental implants that have ferromagnetic properties and are unsafe at 3.0 T. * Pregnant women are not eligible for participating in this study. * Acute claustrophobia
References
Publications (0)
Data not yet available
No reference posted for this study.